Sacituzumab Tirumotecan for Prostate Cancer

(STOP-NEPC Trial)

This trial tests a new treatment called sacituzumab tirumotecan for neuroendocrine prostate cancer (NEPC), particularly in men whose cancer has progressed after platinum-based chemotherapy. The researchers aim to determine if this treatment can effectively control cancer growth. Men diagnosed with NEPC who have not had success with chemotherapy might be suitable for this study. Participants will receive the treatment through an IV (intravenous method). As a Phase 2 trial, this research focuses on measuring the treatment's effectiveness in an initial, smaller group, offering participants a chance to contribute to important advancements in NEPC treatment.

Previous studies have shown that sacituzumab tirumotecan has a manageable safety profile. The most common side effects included anemia (low red blood cell count), a decrease in a type of white blood cell, and mouth inflammation, occurring in about 10% to 15% of patients. Serious side effects related to the treatment occurred in 63% of patients, but no deaths were linked to it. Overall, the treatment appears well-tolerated, with no new safety concerns identified in recent trials.¹²³⁴⁵

Unlike the standard treatments for prostate cancer, which often include hormone therapy, chemotherapy, and radiation, Sacituzumab Tirumotecan offers a novel approach. This drug is an antibody-drug conjugate, which means it combines an antibody specifically targeting cancer cells with a potent chemotherapy agent. This targeted mechanism allows it to deliver the chemotherapy directly to the cancer cells, potentially increasing effectiveness and reducing damage to healthy cells. Researchers are excited about Sacituzumab Tirumotecan because it could provide a more precise and less toxic treatment option for prostate cancer patients.

Research has shown that sacituzumab tirumotecan yields promising results in treating various cancers. In patients with advanced bladder cancer, it shrank tumors in about 31% of cases, meaning nearly one-third of patients saw improvement. The treatment controlled the disease in 71% of patients, effectively stopping the cancer from worsening for many. For prostate cancer, studies found that 47% of patients with previously treated advanced disease responded well, with their tumors shrinking. These findings suggest that sacituzumab tirumotecan might help control and reduce cancer in patients with neuroendocrine prostate cancer. Participants in this trial will receive sacituzumab tirumotecan to evaluate its effectiveness specifically for prostate cancer.²³⁵⁶⁷